Urology Prior Authorization and Denial Guide
BPH minimally invasive procedure prior authorization criteria, prostate biopsy documentation thresholds, kidney stone treatment selection standards, stress urinary incontinence conservative care requirements, and appeal strategies for urology denials. Grounded in Aetna Medical Policy for BPH treatment, UHC CDG Urology, CMS NCDs and LCDs for urological procedures, and AUA clinical guidelines.
BPH treatment: Urolift (CPT 52441, 52442), Rezum (CPT 53850), and TURP require prior authorization from most commercial payers. Documentation requirements include prostate volume or PSA documentation, AUA symptom score (AUASS), failure of medical management (alpha-blocker and/or 5-alpha reductase inhibitor trial), and urodynamic testing results where indicated. Most payers cover TURP and transurethral procedures without the extensive conservative care documentation required for newer minimally invasive approaches. Cystoscopy for hematuria evaluation requires documentation of the clinical indication.
Prostate cancer treatment: radical prostatectomy (CPT 55842, 55866) and radiation therapy (EBRT, brachytherapy) require prior authorization based on documented pathology and clinical staging. HIFU (CPT 0619T) for focal prostate cancer is considered investigational by most major commercial payers and requires a prior authorization with clinical indication documentation and often a peer-to-peer review. Sacral neuromodulation (CPT 64561, 64581) for OAB or urinary retention requires documentation of failure of behavioral therapy and pharmacological management and a trial period with documented success criterion (≥50% improvement).